Could aspirin diminish the risk of fatality risk in covid-19 cases?

There have been 86 million cases of corona and around 4 million deaths registered to the WHO. In severely affected in-hospital COVID-19 patients, an estimated mortality rate of 11.5% has been reported in a recent study.

According to the researches, the pathogenesis of covid-19 is usually accompanied by a weakened immune system, extreme inflammation, and cardiopulmonary thrombosis. With this observation scientists thought that aspirin may reduce the severity in covid-19 with its anti-platelet aggregation, anti-inflammatory, and anti-lung injury effects.

The data combined from 5 studies revealed that aspirin intake is associated with a 53% reduction in all-cause mortality in COVID-19 patients. In the case of hospitalized COVID-19 patients, the evaluation revealed that the use of aspirin is related to a 49% cutback in in-hospital mortality.  

Aspirin has the triple effects of inhibiting virus replication, anticoagulant, and anti-inflammatory, but it has not received attention in the treatment and prevention of nursing care plans.

In summary, the early use of aspirin in covid-19 patients, which has the effects of inhibiting virus replication, anti-platelet aggregation, anti-inflammatory, and anti-lung injury, is expected to reduce the incidence of severe and critical patients, shorten the length of hospital duration and reduce the incidence of cardiovascular complications.

Resource